Shots:

• Incyte will lead the development- manufacture- and supply of both products. ST will be responsible for the regulatory- distribution- and local marketing related activities in Australia- New Zealand & Singapore
• Tafasitamab + lenalidomide is approved in the US & EU to treat adult patients with r/r DLBCL who are not eligible for ASCT
• Pemigatinib is approved in the US- EU & Japan to treat LA or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that has progressed after one prior line of systemic therapy. In Jan'20- Incyte has entered into a collaboration and license agreement with MorphoSys to develop and commercialize tafasitamab globally

 ­ | Ref: PRNewswire | Image: ECIJA